Novartis Sees Reimbursement Advantage For PCSK9 Launch
Executive Summary
Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.
You may also be interested in...
It's Time For Novartis To Put Its Leqvio Launch Strategy To The Test
Novartis Pharmaceuticals US head Victor Bulto talks to Scrip about the launch of Leqvio; the cholesterol-lowering medicine now approved by the US FDA.
Alnylam Secures $2bn Financing From Blackstone By Monetizing Inclisiran Royalties
Alnylam successfully completed a multi-pronged financing deal with the investment firm, which it will use to fund the development of more RNAi drugs.
Novartis Likes US ‘Buy And Bill’ Market For PCSK9 Drug, But Price Will Be Key
Inclisiran's price relative to existing PCSK9 drugs will be key determinant in payer acceptance. Novartis says pricing will be within cost effectiveness range estimated by ICER.